Corpechot, Christophe

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Corpechot, C., Carrat, F., Gaouar, F., Chau, F., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Schramm, C., Pares, A., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 128

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 127

Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence

Bosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityOrgan Transplantation Techniques and Outcomes

Cited by 114

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

Murillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 107

Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis

Grigorian, A. Y., Mardini, H. E., Corpechot, C., Poupon, R., & Levy, C. (2015) · Clinics and Research in Hepatology and Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 99

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

Murillo Perez, C. F., Goet, J. C., Lammers, W. J., Gulamhusein, A., van Buuren, H. R., Ponsioen, C. Y., Carbone, M., Mason, A., Corpechot, C., Invernizzi, P., et al. (2018) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 88

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

Soret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 78

Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis

Lemoinne, S., Cazzagon, N., El Mouhadi, S., Trivedi, P. J., Dohan, A., Kemgang, A., Ben Belkacem, K., Housset, C., Chretien, Y., Corpechot, C., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 78

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience

Lemoinne, S., Pares, A., Reig, A., Ben Belkacem, K., Kemgang Fankem, A. D., Gaouar, F., Poupon, R., Housset, C., Corpechot, C., & Chazouillères, O. (2018) · Clinics and Research in Hepatology and Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 74

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists

Trivedi, P. J., Corpechot, C., Pares, A., & Hirschfield, G. M. (2016) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 71

Significance of antibodies to soluble liver antigen/liver pancreas: a large French study

Eyraud, V., Chazouilleres, O., Ballot, E., Corpechot, C., Poupon, R., & Johanet, C. (2009) · Liver International

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 58

Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis

Corpechot, C., Poujol‐Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R. E., & Poupon, R. (2004) · Liver International

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 48

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Corpechot, C., Chazouillères, O., Rousseau, A., Guyader, D., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 45

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 34

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 20

Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases

Corpechot, C. (2016) · Clinics in Liver Disease

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 19

P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis

Cheung, A. C., Lammers, W. J., Hirschfield, G. M., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., Pares, A., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 12

Focus on liver function abnormalities in patients with Turner syndrome: risk factors and evaluation of fibrosis risk

Bourcigaux, N., Dubost, E., Buzzi, J.-C., Donadille, B., Corpechot, C., Poujol-Robert, A., & Christin-Maitre, S. (2023) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

Cited by 8

Fibroscan improves the ability of the new prognostic scoring systems to predict outcomes of PBC

Corpechot, C., Gaouar, F., Lemoinne, S., Kemkang, A., Poupon, R., Chrétien, Y., Housset, C., & Chazouillères, O. (2016) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 4